Industry News, News, Patient Care

FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight

March 13, 2024
Heart hands

Semaglutide (Wegovy; Novo Nordisk) gained another indication, as the FDA expanded its approved uses to include prevention of cardiovascular death, myocardial infarction, and stroke in adult patients who have cardiovascular disease (CVD) and overweight or obesity.

The new indication was granted after a priority review process and was based on results from the SELECT cardiovascular outcomes trial (NCT03574597). Findings from SELECT showed that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE)—cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke)—by 20% compared with placebo when added to standard of care.

Read more at AJMC >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Bill Regulating Indiana Med Spas Has Passed: What You Need to Know and Why Collective Advocacy Matters
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available
    • Terri Ross Consulting Appoints Cameron Hemphill as Chief Operating Officer and Strategic Advisor